Pharmaceutical

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Small-Cell Lung Cancer: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Small-Cell Lung Cancer.

Apr 19, 2024 - 00:00
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Small-Cell Lung Cancer.
Read the original article

Tags:

Previous Article

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Hepatocellular Carcinoma...

Next Article

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Non-Hodgkin Lymphoma: Li...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Listen: Explaining the E.U.’s pharma overhaul, Lilly’s booming business, & a long-awaited drug approval

Listen: Explaining the E.U.’s pharma overhaul, Lilly’s ...

Apr 27, 2023

STAT+: Califf criticizes insurers for doing too little on drug research

STAT+: Califf criticizes insurers for doing too little ...

Mar 19, 2023

STAT+: White House touts efforts to stem cancer drug shortages

STAT+: White House touts efforts to stem cancer drug sh...

Sep 12, 2023